Effectiveness of A Compound Formulation of Suranjan in The Treatment of Niqras (Gout) - A Pilot Clinical Study

Abstract Niqras (Gout) in Unani medicine is a well-documented condition described in classical texts as a form of Waja-ul-Mafasil (arthritis), characterized by the deposition of Monosodium Urate (MSU) crystals in the joints, causing inflammation and pain. Unani physicians like Ibn Sina and Buqrat (Hippocrates) have elaborated on its etiology and treatment, associating it with an excess of Balgham (phlegm) in the body. Modern pharmacological treatments for gout often come with side effects, but Unani medicine, particularly the use of Suranjan (Colchicum autumnale), has shown promise in managing this disease safely and effectively. This study aims to evaluate the safety and efficacy of a compound formulation of Suranjan in patients with Niqras (Gout) by monitoring changes in serum uric acid levels and improvements in joint pain and inflammation. A pilot clinical study was conducted with 10 patients over a period of one month, administering Majoon-e-Suranjan for non-diabetic patients and Sufoof Majoon-e-Suranjan for diabetic patients. The study demonstrated significant reductions in serum uric acid levels and alleviation of clinical symptoms without any notable adverse effects. These findings suggest that Suranjan may serve as an effective treatment for Niqras. The pilot study indicates that Suranjan is a promising alternative for managing Niqras in Unani medicine, warranting further large-scale clinical trials.